13 HFpEF with obesity phenotype is characterized by greater symptom severity, worse functional capacity, more adverse hemodynamics, and greater risk of heart failure hospitalization than those with HFpEF without obesity
This translates to a difference of 6.5% in mean weight decrease, compared with 20.2% for those receiving semaglutide, a 14% weight decrease
With these drugs proliferation and increased availability, it is crucial to stay current on new findings about how these medications may affect other aspects of the patients health and medical care
While this approach works well at first, it has a high hidden cost: tracking can become fragmented, making early metabolic wins hard to see
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
Have more questions before you schedule a new patient visit